Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Lymphoma 4Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2Small Cell Lung Carcinoma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Extensive Stage Small Cell Lung Cancer 1Congenital Abnormalities 1Central Nervous System Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Neuroendocrine 1Burkitt Lymphoma 1Brain Neoplasms 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cisplatin 4Pemetrexed 3Etoposide 3Topotecan 2Gemcitabine 2Carboplatin 2vosaroxin 1vinflunine 1veliparib 1taxane 1pomalidomide 1pembrolizumab 1liposomal doxorubicin 1etoposide phosphate 1enzalutamide 1apalutamide 1abiraterone 1Vinorelbine 1Tomography, X-Ray Computed 1Temozolomide 1Radiation 1RRx-001 1Positron-Emission Tomography 1Podophyllotoxin 1Platinum 1Paclitaxel 1Irinotecan 1Histamine Antagonists 1GSK2879552 1Epinephrine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Small Cell × Podophyllotoxin × Clear all
NCT01642251 2023-05-06

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
156 enrolled 13 charts
EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Neuroendocrine, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡